New Alzheimer's drug under close watch: can lecanemab slow memory loss?

NCT ID NCT06741553

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study follows 120 people with early Alzheimer's or mild cognitive impairment who are taking lecanemab, an FDA-approved drug that targets amyloid plaques in the brain. Researchers will track changes in memory, daily function, and brain scans over 18 months to see if the drug slows decline. They will also watch for side effects like brain swelling or small bleeds.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Lecanemab
What this could lead to: If successful, this could confirm that lecanemab slows cognitive decline in early Alzheimer's, offering a disease-modifying option for patients.
What could go wrong: This is an observational follow-up, not a new treatment test. Lecanemab can cause brain swelling or microbleeds (ARIA), and benefits may be modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT (MCI)

Contacts and locations

Locations

Affiliated Hospital, School of Medicine, Zhejiang University, China
RECRUITING

Hangzhou, Zhejiang, 310009, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.